Currently, there are 33.19M common shares owned by the public and among those 25.01M shares have been available to trade.
The company’s stock has a 5-day price change of -12.96% and -24.40% over the past three months. LXEO shares are trading -57.14% year to date (YTD), with the 12-month market performance down to -81.20% lower. It has a 12-month low price of $1.45 and touched a high of $19.50 over the same period. LXEO has an average intraday trading volume of 972.63K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.38%, -9.98%, and -56.52% respectively.
Institutional ownership of Lexeo Therapeutics Inc (NASDAQ: LXEO) shares accounts for 82.00% of the company’s 33.19M shares outstanding.
It has a market capitalization of $93.62M and a beta (3y monthly) value of 0.88. The earnings-per-share (ttm) stands at -$3.31. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.53% over the week and 11.11% over the month.
Earnings per share for the fiscal year are expected to increase by 5.97%, and 21.62% over the next financial year. EPS should grow at an annualized rate of 10.95% over the next five years, compared to -99.98% over the past 5-year period.
Looking at the support for the LXEO, a number of firms have released research notes about the stock. Robert W. Baird stated their Outperform rating for the stock in a research note on June 13, 2024, with the firm’s price target at $28. H.C. Wainwright coverage for the Lexeo Therapeutics Inc (LXEO) stock in a research note released on June 06, 2024 offered a Buy rating with a price target of $22. Stifel was of a view on November 28, 2023 that the stock is Buy, while RBC Capital Mkts gave the stock Outperform rating on November 28, 2023, issuing a price target of $22. Leerink Partners on their part issued Outperform rating on November 28, 2023.
